期刊文献+

抗体介导的排斥反应在器官移植中的研究进展 被引量:2

Antibody-mediated rejection in organ transplantation:research progress
原文传递
导出
摘要 器官移植是各种终末期疾病的最终治疗手段,新型免疫抑制剂的应用使细胞性排斥反应得到有效控制,而体液性排斥反应即供体特异性抗体介导的排斥反应仍是造成移植失败甚至受体死亡的重要因素。抗体介导的排斥反应在超急性排斥反应和慢性排斥反应的发生、发展中起着重要作用,但目前医学界对抗体介导的排斥反应的认识还很有限。本文就抗体介导的排斥反应的发生机制、检测与治疗等方面进行综述。 Organ transplantation is the ultimate treatment for various end-stage diseases,and cellular rejection has been effectively controlled due to the application of new immunosuppressants.However,humoral rejection,that is,the rejection mediated by donor-specific antibodies,is still an important factor leading to graft failure or even death of recipients.Antibody-mediated rejection plays a significant role in the development and progression of hyperacute rejection and chronic rejection,but the understanding is still limited in the medical community.This article reviews the mechanism,detection and treatment of antibody-mediated rejection.
作者 刘浩 宋少华 杨璟辉 倪之嘉 傅志仁 LIU Hao;SONG Shao-hua;YANG Jing-hui;NI Zhi-jia;FU Zhi-ren(Department of Organ Transplantation,Changzheng Hospital,Naval Medical University(Second Military Medical University),Shanghai 200003,China)
出处 《第二军医大学学报》 CAS CSCD 北大核心 2021年第11期1284-1289,共6页 Academic Journal of Second Military Medical University
基金 国家自然科学基金(81801590,81970563)。
关键词 器官移植 供体特异性抗体 体液性排斥反应 抗体介导的排斥反应 发生机制 检测 治疗 organ transplantation donor-specific antibody humoral rejection antibody-mediated rejection mechanism detection therapy
  • 相关文献

参考文献3

二级参考文献40

  • 1慢性乙型肝炎防治指南[J].肝脏,2005,10(4):348-357. 被引量:272
  • 2Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201-209.
  • 3Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555-1561.
  • 4Everly M J, Terasaki PI, Trivedi HL, Deng C, Hopfield J, Kaneku H, et al. Proteasome inhibition spares protective immunity while removing donor specific HLA antibodies. Am J Transplant 2010; 10 (Suppl 4): 146.
  • 5Neumann J, Schio S, Tarrasconi H, Bortolotto A, Costa C, Machuca T, et al. Bortezomib in lung transplantation: a promising start. Clin Transpl 2009: 421-424.
  • 6Raghavaiah SR, Daiwan TS, Burns JM, Gloor JM, Gandhi MJ, Winters JL, et al. Depletion of alloantibody-secreting plasma cells by proteasome inhibition improves desensitization. Am J Transplant 2010; 10 (Suppl 4): 44.
  • 7Walsh RC, Rike Shields A, Wall GE, Brailey P, Gimita A, Cardi M, et al. A prospective, staged trial of proteasome inhibitor-based therapy for reduction of HLA sensitization in kidney transplant candidates. Am J Transplant 2010; 10 (Suppl 4): 44.
  • 8Wahrmann M, Haidinger M, Kormoczi GF, Weichhart T, Saemann MD, Geyeregger R, et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010; 89:1385-1390.
  • 92008 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998-2007. In: U.S. Department of Health and Human Services HRaSA, Healthcare Systems Bureau, Division of Transplantation. Rockville; 2008.
  • 10Cecka JM. Kidney transplantation in the United States. Clin Transpl 2008: 1-18.

共引文献17

同被引文献7

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部